Hong-Yang Lu1, Zhen-Yi Lu2, Qiao-Yuan Cheng3, Ju-Fen Cai4, Xiao-Jia Wang1, Yi-Ping Zhang1, Cai-Jin Lou4, Xin-Min Yu4, Jing Qin4, Wei-Wu Ye4, Lei Lei4, Jian Huang4, Hui-Yi Yang5, Wei-Min Mao1. 1. Zhejiang Key Laboratory of Diagnosis & Treatment Technology on Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, PRC. 2. Department of Oncology, Xiangshan First People's Hospital, Xiangshan 315700, PRC. 3. Department of Traditional Chinese Medicine, Zhejiang Institute for Food and Drug Control, Hangzhou 310004, PRC. 4. Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, PRC. 5. Surexam bio-Tech co. Ltd., Guangzhou Technology Innovation Base, Science city, Guangzhou 510663, PRC.
Abstract
BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) such as erlotinib and gefitinib are targeted drugs for the kinase domain of EGFR. They are widely used for the treatment of non-small cell lung cancer (NSCLC). The EGFR exon 19 deletion mutation and the L858R mutation in exon 21 comprise approximately 90% of the somatic mutations in NSCLC patients that respond to EGFR TKI. Several recent studies have also reported that small cell lung cancer (SCLC) patients with EGFR mutations responded to gefitinib. Further study, however, has been limited due to the difficulty obtaining tumor specimens from SCLC patients. OBJECTIVES: The aim of this study was to explore the EGFR mutation status in SCLC patients by plasma analysis. MATERIAL AND METHODS: Plasma samples from SCLC patients were collected for mutant-enriched liquidchip (MEL) analysis to identify the EGFR mutations in exon 19 and 21. RESULTS: The exon 19 deletion mutation was detected in one out of 35 patients (a female non-smoker). No exon 21 mutations were found. CONCLUSIONS: A prevalence of EGFR mutations in SCLC is rare, and occurs most frequently in females and nonsmokers.
BACKGROUND:Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) such as erlotinib and gefitinib are targeted drugs for the kinase domain of EGFR. They are widely used for the treatment of non-small cell lung cancer (NSCLC). The EGFR exon 19 deletion mutation and the L858R mutation in exon 21 comprise approximately 90% of the somatic mutations in NSCLCpatients that respond to EGFR TKI. Several recent studies have also reported that small cell lung cancer (SCLC) patients with EGFR mutations responded to gefitinib. Further study, however, has been limited due to the difficulty obtaining tumor specimens from SCLCpatients. OBJECTIVES: The aim of this study was to explore the EGFR mutation status in SCLCpatients by plasma analysis. MATERIAL AND METHODS: Plasma samples from SCLCpatients were collected for mutant-enriched liquidchip (MEL) analysis to identify the EGFR mutations in exon 19 and 21. RESULTS: The exon 19 deletion mutation was detected in one out of 35 patients (a female non-smoker). No exon 21 mutations were found. CONCLUSIONS: A prevalence of EGFR mutations in SCLC is rare, and occurs most frequently in females and nonsmokers.
Authors: Bradford J Siegele; Konstantin Shilo; Bo H Chao; David P Carbone; Weiqiang Zhao; Olga Ioffe; Wilbur A Franklin; Martin J Edelman; Dara L Aisner Journal: Lung Cancer Date: 2016-02-26 Impact factor: 5.705